Biology of ovarian cancer

Current Opinion in Oncology

Volumn 9, Issue 5, 1997, Pages 465-470

  McCluskey, Lisa L ^a   Dubeau, Louis ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P53; TELOMERASE;

CARCINOGENESIS; CHROMOSOME; DNA METHYLATION; EPITHELIUM CELL; FEMALE; GENE MUTATION; GENETIC PREDISPOSITION; HETEROZYGOSITY LOSS; HUMAN; MESOTHELIUM; MOLECULAR GENETICS; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0030759878     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199709050-00011     Document Type: Review

References (60)

1. Cheng P, Schmutte C, Cofer KF, Felix JC, Yu MC, Dubeau L: Alterations in DNA methylation are early, but not initial, events in ovarian tumorigenesis. Br J Cancer 1993, 75:396-402. This study examines differences in global DNA methylation between ovarian cystadenomas, LMP tumors, and carcinomas. The results support the idea that cystadenomas are fundamentally different from the more aggressive tumors at the molecular genetic level.
2. Sainz de la Cuesta R, Eichhorn JH, Rice LW, Fuller AF Jr, Nikrui N, Goff BA: Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol 1996, 60:238-244.
3. Jimbo H, Hitomi Y, Yoshikawa H, Yano T, Momoeda M, Sakamoto A, Tsutsumi O, Taketani Y, Esumi H: Evidence for monoclonal expansion of epithelial cells in ovarian endometrial cysts. Am J Pathol 1997, 150:1173-1178.
4. Tsao S-W, Mok C-H, Knapp RC, Oike K, Muto MG, Welch WR, Goodman HM, Sheets EE, Berkowitz RS, Lau CC: Molecular genetic evidence of a unifocal origin for human serous ovarian carcinoma. Gynecol Oncol 1993, 48:5-10.
5. Li S, Resnik E, Carcangiu ML, Schwartz PE, Yang-Feng TL: Advanced ovarian carcinoma: molecular evidence of unifocal origin. Gynecol Oncol 1993, 51:21-25.
6. Gallion HH, Guarino DA, DePriest PD, van Nagell JR Jr, Vaccarello L, Berek JS, Pieretti M: Evidence for unifocal origin in familial ovarian cancer. Am J Obstet Gynecol 1996, 174:1102-1108.
7. Zanetta GM, Keeney GL, Kimlinger TK, Katzmann JA, Podratz KC: Concordance of DNA ploidy pattern as measured by flow cytometry in primary, metastatic, and persistent ovarian cancer. Gynecol Oncol 1996, 60:213-216. Molecular genetic evidence for a unifocal origin of ovarian epithelial cancer.
8. Ben-Baruch G, Sivan E, Moran O, Rizel S, Menczer J, Seidman DS: Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian serous carcinoma. Gynecol Oncol 1996, 60:393-396.
9. Wolf NG, Abdul-Karim FW, Schork NJ, Schwartz S: Origins of heterogeneous ovarian carcinoma: a molecular cytogenetic analysis of histologically benign, low malignant potential, and fully malignant components. Am J Pathol 1996, 149:511-520.
10. Zheng J, Wan M, Zweizig S, Yu MC, Dubeau L: Histologically benign or low-grade malignant tumors adjacent to high-grade ovarian carcinomas contain molecular characteristics of high-grade carcinomas. Cancer Res 1993, 53:4138-4142.
11. Zheng J, Benedict WF, Xu H-J, Hu S-X, Kim TM, Velicescu M, Wan M, Cofer KF, Dubeau L: Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas. J Natl Cancer Inst 1995, 87:1146-1153. By examining concordance of genetic abnormalities in ovarian carcinomas and contiguous benign-looking cysts, Wolf et al. [9••], Zheng et al. [10•], and Zheng et al. [11••] address the issue of whether or not the benign-looking components are precursors of the malignant components.
12. Chenevix-Trench G, Kerr J, Hurst T, Shih Y-C, Purdie D, Bergman L, Friedlander M, Sanderson B, Zournazi A, Coombs T, et al.: Analysis of loss of heterozygosity and Kras2 mutations in ovarian neoplasms: clinicopathological correlations. Genes Chromosome Cancer 1997, 18:75-83. This paper compares allelotypes of ovarian cystadenomas, LMP tumors, and carcinomas, and examines ras mutations in the same tumors. The results provide further evidence that these three tumor subtypes are mechanistically different.
13. Mok SC-H, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, Muto MG, Berkowitz RS, Tsao S-W: Mutations of K-ras proto-oncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993, 53:1489-1492
14. Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC, Birrer MJ: p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993, 53:3103-3108.
15. Cheng PC, Gosewehr JA, Kim TM, Velicescu M, Wan M, Zheng J, Felix JC, Cofer KF, Luo P, Biela BH, et al.: Potential role of the inactivated X chromosome in ovarian epithelial tumor development. J Natl Cancer Inst 1996, 88:510-518. This study compares the frequencies of losses of heterozygosity in ovarian cystadenomas, LMP tumors, and carcinomas, and formulates a genetic model of ovarian tumor development based on the findings.
16. Seidman JD, Kurman RJ: Subclassification of serous borderline tumors of the ovary into benign and malignant types: a clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 1996, 20:1331-1345. This paper formulates provocative thoughts on the subclassification and biologic behavior of LMP tumors based on the results of a clinicopathologic study of advanced cases.
17. Schultz DC, Vanderveer L, Berman DB, Hamilton TC, Wong AJ, Godwin AK: Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Res 1996, 56:1997-2002.
18. Johnson SW, Lissy NA, Miller PD, Testa JR, Ozols RF, Hamilton TC: Identification of zinc finger mRNAs using domain-specific differential display. Anal Biochem 1996, 236:348-352.
19. Schneider J, Romero H, Ruiz R, Centeno MM, Rodriguez-Escudero FJ: Nm23 expression in advanced and borderline ovarian carcinoma. Anticancer Res 1996, 16:1197-1202.
20. Srivatsa PJ, Cliby WA, Keeney GL, Dodson MK, Suman VJ, Roche PC, Podratz KC: Elevated nm23 protein expression is correlated with diminished progression-free survival in patients with epithelial ovarian carcinoma. Gynecol Oncol 1996, 60:363-372. This study provides evidence that nm23 protein expression is a prognostic determinant for ovarian cancer.
21. Mok SC, Chan WY, Wong KK, Muto MG, Berkowitz RS: SPARC, an extracellular matrix protein with tumor-suppressing activity in ovarian epithelial cells. Oncogene 1996, 12:1895-1901.
22. Bryan EJ, Watson R, Davix M, Hitchcock A, Foulkes WD, Campbell IG: Localization of an ovarian cancer tumor suppressor gene to a 0.5-cM region between D22S284 and CYP2D, on chromosome 22q. Cancer Res 1996, 56:719-721.
23. Devlin J, Elder P, Gabra H, Steel CM, Knowles MA: High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci. Oncogene 1996, 12:420-423.
24. Bandera CA, Takahashi H, Behbakht K, Liu PC, LiVolsi VA, Benjamin I, Morgan MA, King SA, Rubin SC, Boyd J: Deletion mapping of two potential chromosome 14 tumor suppressor gene loci in ovarian carcinoma. Cancer Res 1997, 57:513-515.
25. Lu KH, Weitzel JN, Kodali S, Welch WR, Berkowitz RS, Mok SC: A novel 4-cM minimally deleted region on chromosome 11p15.1 associated with high grade nonmucinous epithelial ovarian carcinomas. Cancer Res 1997, 57:387-390.
26. Davis M, Hitchcock A, Foulkes WD, Campbell IG: Refinement of two chromosome 11q regions of loss of heterozygosity in ovarian cancer. Cancer Res 1996, 56:741-744.
27. Thompson FH, Nelson MA, Trent JM, Guan X-Y, Liu Y, Yang J-M, Emerson J, Adair L, Wymer J, Balfour C, et al.: Amplification of 19q13.1-q13.2 sequences in ovarian cancer: G-band, FISH, and molecular studies. Cancer Genet Cytogenet 1996, 87:55-62.
28. Merajver SD, Pham TM, Caduff RF, Chen M, Poy EL, Cooney KA, Weber BL, Collins FS, Johnston C, Frank TS: Somatic mutations in the BRCA1 gene in sporadic ovarian tumors. Nature Genet 1995, 9:439-443.
29. Takahashi H, Behbakht K, McGovern PE, Chiu H-C, Couch FJ, Weber BL, Friedman LS, King M-C, Furusato M, LiVolsi VA, et al.: Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 1995, 55:2998-3002.
30. Takahashi H, Chiu H-C, Bandera CA, Behbakht K, Liu PC, Couch FJ, Weber BL, LiVolsi VA, Furusato M, Rebane BA, et al.: Mutations of the BRCA2 gene in ovarian cancer. Cancer Res 1996, 56:2738-2741.
31. Schultz DC, Vanderveer L, Buetow K, Boente MP, Ozols RF, Hamilton TC, Goodwin AK: Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res 1995, 55:2150-2157.
32. Wan M, Cofer KF, Dubeau L: WAF1/CIP1 structural abnormalities do not contribute to cell cycle deregulation in ovarian cancer. Br J Cancer 1996, 73:1398-1400.
33. Dodson MK, Cliby WA, Xu H-J, DeLacey KA, Hu S-X, Keeney GL, Li J, Podratz KC, Jenkins RB, Benedict WF: Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus. Cancer Res 1994, 54:610-613.
34. Kim TM, Benedict WF, Xu H-J, Hu S-X, Gosewehr J, Velicescu M, Yin E, Zheng J, D'Ablaing G: Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression. Cancer Res 1994, 54:605-609.
35. Worsley SD, Ponder BAJ, Davies BR: Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol Oncol 1997, 64:189-195.
36. Wan M, Li W-Z, Duggan BD, Felix JC, Zhao Y, Dubeau L: Telomerase activity in benign and malignant epithelial ovarian tumors. J Natl Cancer Inst 1997, 89:437-441. This study compares telomerase expression in ovarian cystadenomas, LMP tumors, and carcinomas. The results provide further evidence that cystadenomas are fundamentally different from the more aggressive tumors at the molecular genetic level.
37. Vuento MH, Pirhonen JP, Makinen JE, Laippala PJ, Gronroos M, Salmi TA: Evaluation of ovarian findings in asymptomatic postmenopausal women with color Doppler ultrasound. Cancer 1995, 76:1214-1218
38. McManus DT, Murphy M, Arthur K, Hamilton PW, Russell SEH, Toner PG: P53 mutation, allele loss on chromosome 17p, and DNA content in ovarian carcinoma. J Pathol 1996, 179:177-182.
39. Iwabuchi H, Sakamoto M, Sakunaga H, Ma YY, Carcangiu ML, Pinkel D, Yang-Feng TL, Gray JW: Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res 1995, 55:6172-6180. The first study to use comparative genomic hybridization to compare chromosomal changes between ovarian cystadenomas, LMP tumors, and carcinomas.
40. Boyd J, Rubin SC: Hereditary ovarian cancer: molecular genetics and clinical implications. Gynecol Oncol 1997, 64:196-206.
41. Salazar H, Godwin AK, Daly MB, Laub PB, Hogan M, Rosenblum N, Boente MP, Lynch HT, Hamilton TC: Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 1996, 88:1810-1820. Evidence for the existence of specific morphologic changes in prophylactic oophorectomy specimens from patients with familial predisposition to ovarian carcinoma. These results have implications for the identification of a precursor lesion for ovarian carcinoma.
42. Wan M, Sangiorgi F, Felix JC, Dubeau L: Association of BRCA1 with gonadotropin-responsive cells. Lancet 1996, 348:192-193. This study points to a possible physiologic explanation for the known association between ovulatory activity and ovarian cancer predisposition.
43. Fisk B, Hudson JM, Kavanagh J, Wharton JT, Murray JL, Ioannides CG, Kudelka AP: Existent proliferative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides. Anticancer Res 1997, 17:45-54.
44. Fischer-Colbrie J, Witt A, Heinzel H, Speiser P, Czerwenka K, Sevelda P, Zellinger R: EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res 1997, 17:613-620.
45. Chow S-N, Lin J-K, Li SS-L, Chien C-H: Identification of LDH-ras p21 protein complex and expression of these genes in human ovarian cancer. Gynecol Oncol 1997, 64:114-120.
46. Kanety H, Kattan M, Goldberg I, Kopolovic J, Ravia J, Menczer J, Karasik A: Increased insulin-like growth factor binding protein-2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid. Br J Cancer 1996, 73:1069-1073.
47. Mattern J, Stammler G, Koomagi R, Wallwiener D, Kaufman M, Volm M: Association of vascular endothelial growth factor expression with tumor cell proliferation in ovarian carcinoma. Anticancer Res 1997, 17:621-624.
48. Meden H, Marx D, Schauer A, Wuttke W, Kuhn W: Prognostic significance of p105 (c-erbB-2, HER2/neu) serum levels in patients with ovarian cancer. Anticancer Res 1997, 17:757-760.
49. Ottensmeier C, Swanson L, Strobel T, Druker B, Niloff J, Cannistra SA: Absence of constitutive EGF receptor activation in ovarian cancer cell lines. Br J Cancer 1996, 74:446-452.
50. Skubitz AP, Bast RC Jr, Wayner EA, Letourneau PC, Wilke MS: Expression of alpha 6 and beta 4 integrins in serous ovarian carcinoma correlates with expression of the basement membrane protein laminin. Am J Pathol 1996, 148:1445-1461.
51. Wiener JR, Kassim SK, Yu Y, Mills GB, Bast RC Jr: Transfection of human ovarian cancer cells with the HER-2/neu receptor tyrosine kinase induces a selective increase in PTP-H1, PTP-1B, and PTP-alpha expression. Gynecol Oncol 1996, 61:233-240,
52. Abrahamsson G, Janson PO, Kullander S: Steroid release from two human epithelial ovarian tumors: evidence for an instrinsic production in vitro. Gynecol Oncol 1997, 64:99-104.
53. Abu-Jawdeh GM, Jacobs TW, Niloff J, Cannistra SA: Estrogen receptor expression is a common feature of ovarian borderline tumors. Gynecol Oncol 1996, 60:301-307.
54. Di Simone N, Crowley WF Jr, Wang Q-F, Sluss PM, Schneyer AL: Characterization of inhibin/activin subunit, follistatin and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Endocrinol 1996, 137:486-494.
55. Geisler JP, Wiemann MC, Miller GA, Geisler HE: Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary. Gynecol Oncol 1996, 60:424-427. The controversial issue of the consequences of steroid hormone receptor expression status on prognosis of a specific subgroup of ovarian carcinomas is addressed.
56. Chambers SK, Gertz RE Jr, Ivins CM, Kacinski BM: The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer. Cancer 1995, 75:1627-1633.
57. Chambers SK, Yang Y, Gertz RE, Kacinski BM: Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase. Cancer Res 1995, 55:1578-1585.
58. Speiser P, Mayerhofer K, Kucera E, Roch G, Mittelbock M, Gitsch G, Zeillinger R: PS2 and PAI-1 in ovarian cancer: correlation to pathohistological parameters. Anticancer Res 1997, 17:679-684.
59. Van den Brule FA, Buicu C, Berchuck A, Bast RC Jr, Deprez M, Lui FT, Cooper DN, Pieters C, Sobel ME, Castronovo V: Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Human Pathol 1996, 27:1185-1191.
60. Young TN, Rodriguez GC, Rinehart AR, Bast RC Jr, Pizzo SV, Stacks MS: Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol 1996, 62:89-99.